GSK and Hitachi Chemical Signs a Three-year Agreement for T-cell Therapy
Shots:
- Hitachi Chemical’s subsidiary HCATS (Hitachi Chemical Advanced Therapeutics Solutions)- will manufacture GSK’s SPEAR T-cell receptor therapy targeting NY-ESO-1 for the US- Canadian and European trials
- The agreement focuses on providing- compliant- flexible- scalable- and cost-effective therapies accessible to cancer patients
- NY-ESO-1 is a human tumor antigen expressed in sarcomas- melanoma- multiple myeloma- bladder cancer- NSCLC- ovarian cancer and gastro-intestinal cancers
Ref: Businesswire | Image: GSK
Click here to read the full press release
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com